Abstract
Background & aims An observational association between nonalcoholic fatty liver disease (NAFLD) and kidney function impairment has been reported. A genetic variant linked to an increased risk of NAFLD, the G allele of rs738409, has been reported to be associated with a reduction in estimated glomerular filtration rate (eGFR).
Methods In this Mendelian randomization (MR) study, we selected rs738409 as a genetic instrument to predict NAFLD. The genetic variant rs13107325, which is strongly associated with the steatohepatitis marker liver MRI corrected T1 score, was introduced as an alternate genetic instrument for the NAFLD-related phenotype. The eGFR outcome was assessed in individuals of white British ancestry included in the UK Biobank (N = 321,260), and associations adjusted for major metabolic disorder and income grades were investigated. Further, the associations were reassessed in two negative control subgroups (body mass index < 25 kg/m2 and serum alanine aminotransferase level < 20 IU/mL) with a low probability of developing NAFLD. As a replication analysis, a summary-level MR was performed with the European ancestry CKDGen dataset (N = 567,460).
Results In the UK Biobank dataset, a genetic predisposition for NAFLD or an increased liver T1 score was significantly associated with a reduced eGFR with adjustment for major metabolic disorders. Although the associations were not significant in the negative control subgroups with a low probability of developing NAFLD, they were significant in the subgroups with a remaining risk of NAFLD, suggesting the absence of a horizontal pleiotropic pathway. The summary-level MR from the CKDGen dataset supported the causal effects of NAFLD on reduced eGFR.
Conclusions This MR analysis supports the causal reduction in eGFR by NAFLD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Industrial Strategic Technology Development Program - Development of biocore technology (10077474, Development of early diagnosis technology for acute/chronic renal failure) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from SNU R&DB Foundation (800-20190571). The study was performed independently by the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards of Seoul National University Hospital (E-2010-007-1160). The requirement for informed consent was waived as we investigated anonymous public databases. The investigation of the UK Biobank was approved by the consortium (No. 53799).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data for this study is available in the public domain.
